Clinical Trial Update: A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1b dose-escalation study of PSK with docetaxel for metastatic castration-resistant prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• PSK (polysaccharide-K)

Snippet

Sponsor: Bastyr University | Conditions: Prostatic Neoplasms | Phase 1 | Status: WITHDRAWN